急性脑梗死患者尿激酶型纤溶酶原激活物及受体的变化

The change of plasma urokinase-type plasminogen activator and its receptor in patients with acute cerebral infarction

目的探讨急性脑梗死患者血浆尿激酶型纤溶酶原激活物(uPA)及受体(uPAR)的变化和临床意义。方法对66例急性脑梗死患者和30例健康者应用酶联免疫吸附双抗体夹心法(ELISA法)定量测定血浆uPA和uPAR的水平。结果与正常对照组相比,急性脑梗死组uPA含量(4756±632)ng/L,uPAR含量(3102±256)ng/L,明显高于正常对照组的uPA(1075±244)ng/L和uPAR(877±216)ng/L,差异有显著性(P<0.01)。随急性脑梗死患者病情严重程度的加重,血浆uPA和uPAR含量增高越明显。结论急性脑梗死患者血浆uPA和uPAR的水平明显升高,且与急性脑梗死患者的病情密切相关。

Objective To investigate the changes of the plasma urokinase-type plasminogen activator （uPA） and urokinase-type plasminogen activator receptor （uPAR） in patients with acute cerebral infarction and its clinical significance. Methods The plasma level of uPA and uPAR were measured by sandwich ELISA in 66 patients with cerebral infarction and 30 normal healthy subjects. Resalts Compared with uPA （1075±244）ng/L and uPAR（877±216）ng/L in healthy control group, patients with cerebral infarction had higher levels of uPA（4756±632）ng/L and uPAR（3102±256）ng/L, and there was distinct difference（P〈0. 01）. The severer of the patient＇s degree, the higher of uPA and uPAR. Conclusion Plasma uPA and uPAR level increase at early stage in patients with cerebral infarction. The uPA and uPAR levels are closely relative to the severity of patients with cerebral infarction.